BPC-157 (stable gastric pentadecapeptide) rapidly healed duodenocolic fistulas in rats by recruiting blood vessels to both fistula sides within minutes, closing both defects and eliminating leakage, diarrhea, and weight loss.
Complete fistula closureBPC-157 healed both duodenal and colonic defects in rats, with no leakage vs persistent fistulas in controls
What the researchers found
BPC-157 healed duodenocolic fistulas in rats by rapidly inducing vessel recruitment at both fistula sides, with complete defect closure, no leakage, no weight loss, and favorable gene expression changes (elevated NOS-2, decreased COX-2/VEGF-A/NF-κB).
Why it matters
Gastrointestinal fistulas are notoriously difficult to heal and often require complex surgery. A peptide that can induce rapid vascular repair from both sides of a fistula represents a potentially transformative non-surgical approach to this challenging clinical problem.
The numbers in context
BPC 157 at 10 µg/kg and 10 ng/kg; assessed at 3, 6, 9, 12, and 15 minutes after fistula creation; effective both locally and intragastrically.
How the study worked
Animal study in rats with surgically created duodenocolic fistulas. BPC-157 given locally, intragastrically (10 μg/kg, 10 ng/kg), or intraperitoneally. Acute vascular response assessed at 3-15 min. Chronic healing assessed at days 1-28. Gene expression by mRNA analysis.
Who was studied
Rats with experimentally created duodenocolic fistulas
What this study cannot tell us
Animal study in rats — human fistula healing may differ significantly. BPC-157 is not FDA-approved. Surgically created fistulas may not replicate disease-caused fistulas (Crohn's, radiation, etc.). Mechanism of rapid vessel recruitment not fully explained. No clinical trials for this indication.
How to read the evidence
Moderate evidence — well-designed animal study with multiple administration routes, time points, and gene expression data. No human data for this indication.
When this study was published
Published in 2024. Part of the extensive BPC-157 preclinical literature on tissue healing.
The bigger picture
BPC-157 research continues to expand its demonstrated healing capabilities across multiple tissue types. The fistula model is particularly compelling because it requires coordinated healing from two different tissue types (duodenum and colon) simultaneously — a more complex challenge than single-tissue wound healing.
Questions still open
- Can BPC-157 heal fistulas in human patients with Crohn's disease or radiation injury?
- How does BPC-157's vessel recruitment mechanism compare to VEGF and other angiogenic therapies?
- Could BPC-157 be delivered endoscopically to fistula sites in patients?
Common questions
Can a peptide heal an abnormal connection between intestines?
How does BPC-157 heal tissues so quickly?
Read the original research
Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 75(1)
Citation
Vukusic, D; Zenko Sever, A; Sever, M; Drmic, D; Milavic, M; Sikiric, S; Rasic, D; Krezic, I; Gojkovic, S; Prtoric, A; Bubalo, P; Coric, L; Dobric, I; Boban Blagaic, A; Rasic, Z; Skrtic, A; Seiwerth, S; Sikiric, P. (2024). Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 75(1). https://doi.org/10.26402/jpp.2024.1.09